By using these GPC1-expressing PANC02 cells as a model, researchers can precisely monitor and analyze how cytotoxic T cells recognize and react to the GPC1 antigen presented by tumor cells, offering insights into the potential efficacy of GPC1-based immunotherapeutic strategies against pancreatic ductal adenocarcinoma. The gene discussed is GPC1; the disease is neoplasm.